Turkington, Douglas, Kingdon, David and Chadwick, Paul
Cognitive-behavioural therapy for schizophrenia: filling the therapeutic vacuum
British Journal of Psychiatry, 183, (2), .
Full text not available from this repository.
D.T. has accepted hospitality from Pfizer, Lilly, Janssen and Organon. He has undertaken a consultancy for Pfizer, has sat on two advisory boards and has acted as principal investigator on a Pfizer-funded trial into the efficacy of CBT in schizophrenia in community settings. D.K. has received hospitality from Pfizer, Lilly and Janssen and has sat on an advisory board for Pfizer.
Actions (login required)